Role of platelets in restenosis after percutaneous coronary revascularization.

[1]  E. Topol,et al.  Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization , 1997, Annals of the New York Academy of Sciences.

[2]  A. Takeshita,et al.  Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. , 1996, The Journal of clinical investigation.

[3]  M. Savage,et al.  Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) , 1995, Circulation.

[4]  S. Schwartz,et al.  Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. , 1995, Circulation research.

[5]  M. Fishbein,et al.  VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. , 1995, Circulation.

[6]  S. Shattil.  Function and Regulation of the β3 Integrins in Hemostasis and Vascular Biology , 1995, Thrombosis and Haemostasis.

[7]  E. Topol,et al.  Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.

[8]  R. Califf,et al.  Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention , 1995 .

[9]  R. Jordan,et al.  Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. , 1995, Circulation.

[10]  J. Moake,et al.  Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. , 1995, Circulation.

[11]  A. Buchwald,et al.  914-72 Platelet––Stimulated Proliferation of Coronary Smooth Muscle Cells , 1995 .

[12]  S. Fujii,et al.  713-1 inhibition of Neointimal Hyperplasia After Balloon Injury by Local Delivery of a Cyclic Arginine-Glycine-Aspartic Acid Peptide Targeting Vitronectin Receptor , 1995 .

[13]  J. Zablocki,et al.  SC-54684A: an orally active inhibitor of platelet aggregation. , 1995, Circulation.

[14]  D. Mehrotra,et al.  Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. , 1995, Circulation.

[15]  S. L. Brown,et al.  Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. , 1994, Cardiovascular research.

[16]  K. Sakariassen,et al.  A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenoses. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[17]  Joseph F. Murphy,et al.  The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. , 1994, The Biochemical journal.

[18]  H. Deckmyn,et al.  Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. , 1994, Circulation.

[19]  A. Herskowitz,et al.  Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. , 1994, Circulation.

[20]  A. Goodall,et al.  Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. , 1994, Clinical science.

[21]  J. M. Siegel,et al.  A scaling law for wall shear rate through an arterial stenosis. , 1994, Journal of biomechanical engineering.

[22]  S. Mousa,et al.  Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs. , 1994, Thrombosis research.

[23]  R. Califf,et al.  Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. , 1994, Circulation.

[24]  T. Yue,et al.  Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. , 1994, Experimental cell research.

[25]  Gail Murphy,et al.  Pharmacokinetics and pharmacodynamics of MK‐383, a selective non‐peptide platelet glycoprotein‐IIb/IIIa receptor antagonist, in healthy men , 1994, Clinical pharmacology and therapeutics.

[26]  R. Connolly,et al.  Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time. , 1994, The Journal of laboratory and clinical medicine.

[27]  R. Gould,et al.  Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. , 1994, Journal of Medicinal Chemistry.

[28]  G. Rhodes,et al.  The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  M. Todd,et al.  Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model. , 1994, Circulation research.

[30]  R. Calvo,et al.  The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. , 1994, Thrombosis research.

[31]  P. Nurden,et al.  Two-way trafficking of membrane glycoproteins on thrombin-activated human platelets. , 1994, Seminars in hematology.

[32]  J. Calvete.  Clues for Understanding the Structure and Function of a Prototypic Human Integrin: The Platelet Glycoprotein IIb/IIIa Complex , 1994, Thrombosis and Haemostasis.

[33]  Z. Ruggeri.  New insights into the mechanisms of platelet adhesion and aggregation. , 1994, Seminars in hematology.

[34]  A. S. Yuan,et al.  Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[35]  J. Hubbell,et al.  Inhibition of thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel barriers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[37]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[38]  S. Mousa,et al.  Antithrombotic Effects of DMP 728, a Platelet GPIIb/IIIa Receptor Antagonist, in a Canine Model of Arterial Thrombosis , 1994, Journal of cardiovascular pharmacology.

[39]  E. Topol,et al.  Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. , 1994, Circulation.

[40]  Yukio Motoyama,et al.  The pharmacology of the integrins , 1994, Medicinal research reviews.

[41]  S. Schwartz,et al.  Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. , 1994, Circulation research.

[42]  S. Roux,et al.  Experimental carotid thrombosis in the guinea pig. , 1994, Thrombosis and haemostasis.

[43]  J. A. L. Pez,et al.  The platelet glycoprotein Ib-IX complex. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[44]  C. Pally,et al.  The Effects of Two Synthetic Glycoprotein II b/III a Antagonists, Ro 43-8857 and L-700,462, on Platelet Aggregation and Bleeding in Guinea-Pigs and Dogs: Evidence that Ro 43-8857 Is Orally Active , 1993, Thrombosis and Haemostasis.

[45]  P. Nurden,et al.  A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. , 1993, Bailliere's clinical haematology.

[46]  H. Zerwes,et al.  Platelet Aggregation and Fibrinogen Binding in Human, Rhesus Monkey, Guinea-Pig, Hamster and Rat Blood: Activation by ADP and a Thrombin Receptor Peptide and Inhibition by Glycoprotein IIb/IIIa Antagonists , 1993, Thrombosis and Haemostasis.

[47]  E. Topol,et al.  Clinical Trials of Platelet Receptor Inhibitors , 1993, Thrombosis and Haemostasis.

[48]  F. Orr,et al.  Localization of 13-hydroxyoctadecadienoic acid and the vitronectin receptor in human endothelial cells and endothelial cell/platelet interactions in vitro. , 1993, Blood.

[49]  T. Olah,et al.  Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay. , 1993, Journal of pharmaceutical and biomedical analysis.

[50]  D. Faxon,et al.  Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. , 1993, Coronary artery disease.

[51]  P. Hadváry,et al.  Low molecular weight, non-peptide fibrinogen receptor antagonists. , 1992, Journal of medicinal chemistry.

[52]  H. Gralnick,et al.  A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected]. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Ryan,et al.  The effect of antiplatelet therapy on platelet accumulation after experimental angioplasty in the rabbit iliac model. , 1992, International journal of cardiology.

[54]  J. Moake,et al.  Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. , 1992, Blood.

[55]  R. Kramer,et al.  β1 And β3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix , 1992 .

[56]  G. Feuerstein,et al.  Antithrombotic Effects of a Platelet Fibrinogen Receptor Antagonist in a Canine Model of Carotid Artery Thrombosis , 1992, Stroke.

[57]  F. Orr,et al.  Up-regulated biosynthesis and expression of endothelial cell vitronectin receptor enhances cancer cell adhesion. , 1992, Cancer research.

[58]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[59]  M. Savage,et al.  Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty. , 1991, American heart journal.

[60]  P. Serruys,et al.  Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty With Thromboxane A2‐Receptor Blockade: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 1991, Circulation.

[61]  M. Reidy,et al.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1991, Science.

[62]  V. Fuster,et al.  Antithrombotic Therapy for Deep Arterial Injury by Angioplasty: Efficacy of Common Platelet Inhibition Compared With Thrombin Inhibition in Pigs , 1991, Circulation.

[63]  F. Orr,et al.  Endothelial cell damage by Walker carcinosarcoma cells is dependent on vitronectin receptor-mediated tumor cell adhesion. , 1991, The American journal of pathology.

[64]  M. Reidy,et al.  Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[65]  K Watanabe,et al.  The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. , 1991, The Journal of clinical investigation.

[66]  H. Weisman,et al.  Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents a , 1991, Annals of the New York Academy of Sciences.

[67]  S. Albelda,et al.  Integrins and other cell adhesion molecules , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  M. Reidy,et al.  Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[69]  M. Bednarek,et al.  Platelet receptor recognition domain on the gamma chain of human fibrinogen and its synthetic peptide analogues. , 1989, Biochemistry.

[70]  D. Cheresh,et al.  Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. , 1989, The Journal of biological chemistry.

[71]  L Schwartz,et al.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.

[72]  V. Fuster,et al.  Insights into the pathogenesis of acute ischemic syndromes. , 1988, Circulation.

[73]  J. Moake,et al.  Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin , 1988 .

[74]  M. Ginsberg,et al.  Cytoadhesins, Integrins, and Platelets , 1988, Thrombosis and Haemostasis.

[75]  M. Poncz,et al.  Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. , 1987, Biochemistry.

[76]  Xiaoping Du,et al.  Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. , 1987, Blood.

[77]  T. Ryan,et al.  Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. , 1987, Circulation.

[78]  J. Moake,et al.  Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. , 1986, The Journal of clinical investigation.

[79]  V. Fuster,et al.  Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. , 1986, Journal of the American College of Cardiology.

[80]  P. Hagen,et al.  The role of aspirin and dipyridamole on vascular DNA synthesis and intimal hyperplasia following deendothelialization. , 1986, The Journal of surgical research.

[81]  E Ruoslahti,et al.  The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[82]  H. Zola,et al.  Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. , 1985, European journal of biochemistry.

[83]  V. Fuster,et al.  Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.

[84]  B. Coller.  A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. , 1985, The Journal of clinical investigation.

[85]  T. Ryan,et al.  Effect of antiplatelet therapy on restenosis after experimental angioplasty. , 1984, The American journal of cardiology.

[86]  R. Erbel,et al.  Percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris: analysis of early and late results. , 1983, American heart journal.

[87]  A E Becker,et al.  Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration. , 1983, British heart journal.

[88]  J. Joist,et al.  Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. , 1983, The Journal of laboratory and clinical medicine.

[89]  D. Waters,et al.  Percutaneous Transluminal Coronary Angioplasty in Patients with Variant Angina , 1982, Circulation.

[90]  W. Siegenthaler,et al.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.

[91]  A. Nurden,et al.  Specific roles for platelet surface glycoproteins in platelet function , 1975, Nature.

[92]  José A López,et al.  The platelet glycoprotein Ib-IX complex , 2017 .

[93]  T. Yasuda,et al.  Antithrombotic Effects and Bleeding Time Prolongation with Synthetic Platelet GPIIb/llla Inhibitors in Animal Models of Platelet-Mediated Thrombosis , 1994, Thrombosis and Haemostasis.

[94]  S. Mousa,et al.  Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. , 1994, Circulation.

[95]  A. Callow,et al.  Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA , 1994 .

[96]  S. Mousa,et al.  Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. , 1993, Cardiology.

[97]  S. D’Souza,et al.  Ligand Binding to GPIIb-IIIa: A Status Report , 1992, Seminars in thrombosis and hemostasis.

[98]  B. Coller,et al.  Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel , 1991 .

[99]  M. Reidy,et al.  Role of basic fibroblast growth factor in vascular lesion formation. , 1991, Circulation research.

[100]  G. Roth,et al.  Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. , 1991, Blood.

[101]  R. Friedman,et al.  SMOOTH MUSCLE CELL PROLIFERATION AND RE-ENDOTHELIALIZATION , 1977 .